
|Articles|October 24, 2012
Intranasal fentanyl spray benefits compared with oral agents for breakthrough cancer pain
Patients with breakthrough cancer pain (BTCP) may want to consider intranasal fentanyl spray over oral agents to treat their breakthrough pain because of improved onset of analgesia and avoidance of nausea and vomiting, according to a report published online September 25 for The Annals of Pharmacotherapy.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
The Emergence of CGRP-Targeted Therapies is Transforming Migraine Care | NCPA 2025
2
FDA Approves Oral Semaglutide for Risk of MACE for Patients With Diabetes
3
Pharmacists Experience Challenges in Credentialing, Billing for Services | NCPA 2025
4
FDA Approves Tezepelumab for as Add-On Treatment for Chronic Rhinosinusitis With Nasal Polyps
5